Navigation Links
Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients

out CYT003-QbG10

CYT003-QbG10 is an immunotherapeutic product in development for the treatment of allergy, asthma and atopic dermatitis. It consists of the ImmunodrugTM QbG10 which is comprised of the virus-like particle Qb filled with a synthetic immunostimulatory DNA sequence called G10. CYT003-QbG10 is designed to induce a potent Th1 type immune response in order to suppress an “allergic” Th2 type immune response. As initial clinical observations indicate, CYT003-QbG10 could thereby act by an allergen-independent mechanism of action so that it has potential as a causal and disease-modifying treatment for a broad range of different allergic diseases. CYT003-QbG10 is currently being studied in several clinical trials for the treatment of allergic rhinitis, asthma and atopic dermatitis.

About allergic diseases

Allergy as a whole is a multi-faceted disease and clinically manifests in various allergic disorders including allergic rhinitis, asthma, atopic dermatitis and food hypersensitivity. It is an exaggerated reaction by the patient’s immune system to a normally harmless substance such as various environmental proteins present in pollen, animal excrements, or food. According to the World Health Organization, more than 20% of the world population suffers from allergic diseases (WHO, 2002).

Seasonal allergic rhinitis due to grass pollen (commonly known as hay fever) is very common and affects 15-20% of the European population (WHO Europe, 2003). Three general approaches are commonly being pursued to relieve the symptoms of allergic diseases: avoidance of the allergen, prescription of medication that targets disease symptoms, and conventional immunotherapy, also known as desensitization. The latter is the only disease-modifying treatment available, however, it is applicable only for some defined allergies, is time-consuming (3-5 years) and inconvenient for the patients. T
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:2/27/2015)...  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the fourth quarter and full year ended December ... year for PTC. We are now a growing commercial-stage ... in the rare disease space," stated Stuart W. Peltz, ... proud to bring the first treatment for Duchenne muscular ...
(Date:2/27/2015)... Feb. 27, 2015  Bionik Laboratories Corp. (OTC:DWTPD), a ... today that it acquired Bionik Laboratories, Inc., a ... the sale to qualified accredited investors of units consisting ... proceeds of approximately $6.2 million. Shares of the Company,s ... OTC Markets under the symbol "DWTPD" until FINRA,s approval ...
(Date:2/26/2015)... RnRMarketResearch.com adds Corneal Ulcers ... to its store. This report p provides an ... The report "Corneal Ulcers - Pipeline Review, H2 2014" ... Corneal Ulcers. Corneal Ulcers are primarily result of ... infections & fungal infections. The symptoms of the ...
Breaking Medicine Technology:PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5
... To further its continuing partnerships with Brazilian public health ... has appointed Mr. Nelson dos Santos as interim vice ... a scientific nonprofit organization whose mission is to improve ... and related programs that help ensure the quality, safety ...
... FREDERICKSBURG, Va., Jan. 31, 2011 Research to develop more ... disease to cure -- could someday benefit all breast cancer ... Fredericksburg Oncology . "Understanding how triple negative ... give us insight into how other types of breast cancer ...
Cached Medicine Technology:New Interim Leadership for USP-Brazil 2Triple Negative Cancer Research Could Benefit All Breast Cancer Patients 2
(Date:2/28/2015)... 28, 2015 National Sales ... sales, marketing and supply chain management for consumer ... is bringing its award winning solutions for thinning-damaged ... products are specifically created to combat thinning-damaged hair. ... is committed to marrying science with nature to ...
(Date:2/28/2015)... Flagstaff, AZ (PRWEB) February 28, 2015 ... drug and alcohol treatment center , and current student ... State University, has implemented a weekly forum in psychoeducation ... high school in Flagstaff, AZ as part of her ... a big need for support and counseling at the ...
(Date:2/28/2015)... ON (PRWEB) February 28, 2015 The ... Art of Facial Surgery was recently featured in the ... of the magazine, Dr. David Ellis was featured in ... discussed the various cosmetic enhancements that Kim Cattrall has ... , “Her forehead is smooth without horizontal lines ...
(Date:2/28/2015)... February 28, 2015 Plugin creators from ... Volume 2. A fully customizable transition pack ... Volume 2 gives users total control over 30 transition ... CEO of Pixel Film Studios. “TransFold Volume 2 gives ... , TransFold Volume 2 from Pixel Film Studios brings ...
(Date:2/28/2015)... California (PRWEB) February 28, 2015 ... supported and showcased emerging brand at Houston Texas ... in Las Vegas sending its executive delegates headed ... of Business Development and Training Randolph Clarito. , ... (IFA), was held last February 4-7 and featured ...
Breaking Medicine News(10 mins):Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Dr. David Ellis Featured In Elevate Magazine 2Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3
... was true for males tying the knot with younger females, study ... men seven to nine years their junior could be upping their ... with a significantly younger guy raises a woman,s risk of death ... 12 issue of Demography . , Not that marrying much ...
... years ago, scientists at Beth Israel Deaconess Medical Center ... the Akt molecular pathway, a popular target for cancer ... Akt1 was actively preventing cancer cells from ... was actually promoting breast cancer cell migration. And, indeed, ...
... 22q11 deletion syndrome (also known as DiGeorge syndrome) ... having an estimated incidence of at least one ... of severity but a multisystem impact, with symptoms ... endocrine abnormalities, cleft palate, gastrointestinal problems, and neuropsychiatric ...
... National ... was recently awarded certification from the Women’s Business Enterprise National Council (WBENC). ... San Diego, CA ... provider of water conservation and water management services , was ...
... ... extension option with Novation the leading health care supply contracting company for more than 25,000 ... and nearly 15,000 members of Provista, LLC. , ... Santa Clara (Vocus) May 14, 2010 -- Lumenis Ltd., a global leader ...
... out of ten patients who discontinued their overactive bladder (OAB) ... or they couldn,t tolerate it, according to research in the ... US researchers also discovered that smokers, men with enlarged prostates ... to stop taking prescription drugs for bladder problems. The ...
Cached Medicine News:Health News:Women Who Marry Younger Men May Die Earlier 2Health News:Study identifies 1 of the mechanisms behind breast cancer metastasis 2Health News:Without this protein, embryonic development halts 2Health News:National Water Services, Inc. Receives WBE Certification 2Health News:Lumenis Inc. Awarded a 3-year Dual Source Agreement with Novation 2Health News:Lumenis Inc. Awarded a 3-year Dual Source Agreement with Novation 3Health News:Lumenis Inc. Awarded a 3-year Dual Source Agreement with Novation 4Health News:Unmet expectations and smoking prove key factors in quitting bladder medication 2Health News:Unmet expectations and smoking prove key factors in quitting bladder medication 3
... The Gemini Family of infusion ... with a collective series of ... product line offers a wide ... IV sets, each featuring the ...
... These specialty Eraser instruments have ... surgeon with the right tool for ... introduced a series of 25 gauge ... provide discrete treatment of target tissues ...
... itself to over 2,000 medical clinics nation ... user in mind, ChartingPlus relies heavily on ... features to improve documentation quality and increase ... Our medical content is specific to your ...
Transfer your exams to AltaPoint with our EMR Exam Word Lists. Document systems as normal and annotate exceptions to the systems in the exam. AltaPoint EMR is configured to allow a specialty to cust...
Medicine Products: